Skip to main content

liothyronine

Generic: LIOTHYRONINE SODIUM·Brand: CYTOMEL, Cytomel, LIOTHYRONINE SODIUM, TRIOSTAT

liothyronine: developed by 1 company · 2 clinical trials tracked · 1 FDA decision.

liothyronine evidence translation

What we can confirm

1 FDA record · 2 tracked trials

What it means

Source-backed records connect liothyronine to RDY; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could liothyronine → RDY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Thyroid Cancer
Development Pipeline (1)
CompanyPhase
DR REDDYS LABORATORIES LTD (RDY)Approved
Clinical Trials (2)

Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

NCT06647602·N/A·ENTA
Not yet recruiting

Primary endpoint: TSH after two weeks of TH substitution

Observational40 targetStarted 2026-09Completion 2028-122 sites · NetherlandsUniversity Medical Center Groningen

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

NCT04743661·Phase 2

Primary endpoint: 2-year event free survival (EFS) in the Recurrent Medulloblastoma Cohort

Interventionalopen62 targetStarted 2022-04Completion 2027-093 sites · United StatesPediatric Brain Tumor Consortium
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression test(RDY)FDA ↗
ANDA090097OralTablet

Frequently asked questions

Who is developing liothyronine?

liothyronine is being developed by DR REDDYS LABORATORIES LTD.

How many clinical trials involve liothyronine?

BioSniper tracks 2 clinical trials involving liothyronine.

What is liothyronine's latest FDA decision?

The most recent tracked FDA decision for liothyronine is Approval for 1 INDICATIONS AND USAGE Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression test, dated March 20, 2009.